<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Uterine Leiomyosarcoma (ULMS) Research</title>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
  <style>
    :root {
      --primary: #3a86ff;
      --primary-dark: #2667cc;
      --primary-light: #61a0ff;
      --secondary: #ff006e;
      --secondary-light: #ff4b93;
      --dark: #2b3a67;
      --light: #f8f9fa;
      --gray: #6c757d;
      --light-gray: #e9ecef;
      --text: #343a40;
      --white: #ffffff;
      --border-radius: 12px;
      --shadow-sm: 0 2px 8px rgba(0, 0, 0, 0.05);
      --shadow-md: 0 4px 12px rgba(0, 0, 0, 0.08);
      --shadow-lg: 0 8px 24px rgba(0, 0, 0, 0.12);
      --transition: all 0.3s ease;
    }

    * {
      margin: 0;
      padding: 0;
      box-sizing: border-box;
    }

    body {
      font-family: 'Inter', sans-serif;
      line-height: 1.6;
      color: var(--text);
      background-color: var(--light);
      overflow-x: hidden;
    }

    .container {
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 24px;
    }

    /* Typography */
    h1, h2, h3, h4, h5, h6 {
      font-weight: 600;
      line-height: 1.3;
      color: var(--dark);
    }

    p {
      margin-bottom: 1.2rem;
      font-size: 1.05rem;
    }

    ul {
      margin-bottom: 1.2rem;
      padding-left: 1.5rem;
    }

    li {
      margin-bottom: 0.5rem;
    }

    /* Header Styles */
    header {
      width: 100%;
      color: var(--white);
      position: relative;
    }

    .header-top {
      padding: 2.5rem 0;
      background: linear-gradient(135deg, var(--primary), var(--dark));
      text-align: center;
      position: relative;
      z-index: 10;
      transition: transform 0.4s;
    }

    .header-top.hide {
      transform: translateY(-100%);
    }

    nav {
      background-color: rgba(43, 58, 103, 0.95);
      position: relative;
      top: 0;
      left: 0;
      width: 100%;
      box-shadow: var(--shadow-md);
      backdrop-filter: blur(10px);
      transition: var(--transition);
      z-index: 100;
    }

    nav.fixed {
      position: fixed;
      top: 0;
      left: 0;
      width: 100%;
    }

    nav ul {
      display: flex;
      list-style: none;
      justify-content: center;
      flex-wrap: wrap;
      margin: 0;
      padding: 0;
    }

    nav ul li {
      margin: 0;
    }

    nav ul li a {
      display: block;
      color: var(--white);
      text-decoration: none;
      padding: 1rem 1.2rem;
      transition: var(--transition);
      font-weight: 500;
      font-size: 0.95rem;
      position: relative;
    }

    nav ul li a::after {
      content: '';
      position: absolute;
      bottom: 0.5rem;
      left: 50%;
      width: 0;
      height: 2px;
      background-color: var(--white);
      transition: var(--transition);
      transform: translateX(-50%);
      opacity: 0;
    }

    nav ul li a:hover::after {
      width: 30px;
      opacity: 1;
    }

    nav ul li a:hover {
      color: var(--white);
    }

    /* Main Content */
    main {
      padding: 4rem 0;
    }

    section {
      margin-bottom: 5rem;
    }

    .section-title {
      text-align: center;
      margin-bottom: 3rem;
      position: relative;
      padding-bottom: 1.5rem;
    }

    .section-title::after {
      content: '';
      position: absolute;
      bottom: 0;
      left: 50%;
      transform: translateX(-50%);
      width: 80px;
      height: 3px;
      background: linear-gradient(to right, var(--primary), var(--primary-light));
      border-radius: 3px;
    }

    .section-title h2 {
      color: var(--dark);
      font-size: 2.2rem;
      margin-bottom: 0.8rem;
      font-weight: 700;
    }

    .section-title p {
      color: var(--gray);
      font-size: 1.1rem;
      max-width: 600px;
      margin: 0 auto;
    }

    /* Cards */
    .card {
      background-color: var(--white);
      border-radius: var(--border-radius);
      overflow: hidden;
      box-shadow: var(--shadow-md);
      margin-bottom: 2.5rem;
      transition: var(--transition);
      border: 1px solid rgba(0, 0, 0, 0.05);
    }

    .card:hover {
      transform: translateY(-5px);
      box-shadow: var(--shadow-lg);
    }

    .card-header {
      background: linear-gradient(135deg, var(--primary), var(--primary-dark));
      color: var(--white);
      padding: 1.8rem 2rem;
      position: relative;
      overflow: hidden;
    }

    .card-header::before {
      content: '';
      position: absolute;
      top: -50%;
      right: -50%;
      width: 100%;
      height: 100%;
      background: rgba(255, 255, 255, 0.1);
      transform: rotate(45deg);
    }

    .card-header h3 {
      margin-bottom: 0.5rem;
      font-size: 1.5rem;
      position: relative;
      z-index: 1;
      color: var(--white);
    }

    .card-body {
      padding: 2rem;
    }

    /* Content Section */
    .content-section {
      background-color: var(--white);
      padding: 2.5rem;
      border-radius: var(--border-radius);
      box-shadow: var(--shadow-md);
      margin-bottom: 2.5rem;
      border: 1px solid rgba(0, 0, 0, 0.05);
      transition: var(--transition);
    }

    .content-section:hover {
      box-shadow: var(--shadow-lg);
    }

    .content-section h3 {
      color: var(--primary);
      margin-bottom: 1.2rem;
      font-size: 1.5rem;
      position: relative;
      padding-bottom: 0.8rem;
    }

    .content-section h3::after {
      content: '';
      position: absolute;
      bottom: 0;
      left: 0;
      width: 50px;
      height: 3px;
      background: linear-gradient(to right, var(--primary), var(--primary-light));
      border-radius: 3px;
    }

    /* Statistics */
    .stats-container {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));
      gap: 1.8rem;
      margin: 2.5rem 0;
    }

    .stat-item {
      background-color: var(--white);
      padding: 2rem 1.5rem;
      border-radius: var(--border-radius);
      text-align: center;
      box-shadow: var(--shadow-sm);
      transition: var(--transition);
      border: 1px solid rgba(0, 0, 0, 0.05);
      position: relative;
      overflow: hidden;
    }

    .stat-item::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      width: 100%;
      height: 4px;
      background: linear-gradient(to right, var(--primary), var(--primary-light));
    }

    .stat-item:hover {
      transform: translateY(-5px);
      box-shadow: var(--shadow-md);
    }

    .stat-number {
      font-size: 2.8rem;
      font-weight: 700;
      color: var(--primary);
      margin-bottom: 0.8rem;
      line-height: 1.1;
    }

    .stat-label {
      color: var(--gray);
      font-size: 1rem;
      font-weight: 500;
    }

    /* Timeline */
    .timeline {
      position: relative;
      max-width: 900px;
      margin: 3rem auto;
    }

    .timeline::after {
      content: '';
      position: absolute;
      width: 4px;
      background: linear-gradient(to bottom, var(--primary-light), var(--primary));
      top: 0;
      bottom: 0;
      left: 50%;
      margin-left: -2px;
      border-radius: 4px;
    }

    .timeline-item {
      padding: 10px 40px;
      position: relative;
      width: 50%;
      box-sizing: border-box;
      margin-bottom: 2rem;
    }

    .timeline-item:nth-child(odd) {
      left: 0;
    }

    .timeline-item:nth-child(even) {
      left: 50%;
    }

    .timeline-item::after {
      content: '';
      position: absolute;
      width: 24px;
      height: 24px;
      background-color: var(--white);
      border: 4px solid var(--primary);
      border-radius: 50%;
      top: 15px;
      z-index: 1;
      box-shadow: var(--shadow-sm);
      transition: var(--transition);
    }

    .timeline-item:hover::after {
      background-color: var(--primary-light);
    }

    .timeline-item:nth-child(odd)::after {
      right: -16px;
    }

    .timeline-item:nth-child(even)::after {
      left: -16px;
    }

    .timeline-content {
      padding: 1.8rem;
      background-color: var(--white);
      border-radius: var(--border-radius);
      box-shadow: var(--shadow-sm);
      transition: var(--transition);
      border: 1px solid rgba(0, 0, 0, 0.05);
    }

    .timeline-content:hover {
      box-shadow: var(--shadow-md);
    }

    .timeline-content h3 {
      color: var(--primary);
      margin-bottom: 0.8rem;
      font-size: 1.3rem;
    }

    /* Accordion */
    .accordion {
      margin-bottom: 2.5rem;
    }

    .accordion-item {
      margin-bottom: 1rem;
      border-radius: var(--border-radius);
      overflow: hidden;
      box-shadow: var(--shadow-sm);
      background-color: var(--white);
      border: 1px solid rgba(0, 0, 0, 0.05);
      transition: var(--transition);
    }

    .accordion-item:hover {
      box-shadow: var(--shadow-md);
    }

    .accordion-header {
      background-color: var(--white);
      padding: 1.2rem 1.8rem;
      cursor: pointer;
      display: flex;
      justify-content: space-between;
      align-items: center;
      transition: var(--transition);
      border-radius: var(--border-radius);
    }

    .accordion-header:hover {
      background-color: rgba(58, 134, 255, 0.05);
    }

    .accordion-header h3 {
      margin: 0;
      font-size: 1.1rem;
      font-weight: 600;
      color: var(--dark);
    }

    .accordion-icon {
      width: 20px;
      height: 20px;
      position: relative;
      transition: var(--transition);
    }

    .accordion-icon::before,
    .accordion-icon::after {
      content: '';
      position: absolute;
      background-color: var(--primary);
      transition: var(--transition);
    }

    .accordion-icon::before {
      width: 100%;
      height: 2px;
      top: 9px;
    }

    .accordion-icon::after {
      width: 2px;
      height: 100%;
      left: 9px;
    }

    .accordion-content {
      background-color: var(--white);
      padding: 0;
      max-height: 0;
      overflow: hidden;
      transition: max-height 0.4s ease, padding 0.4s ease;
    }

    .accordion-item.active .accordion-header {
      background-color: rgba(58, 134, 255, 0.08);
    }

    .accordion-item.active .accordion-icon::after {
      transform: rotate(90deg);
      opacity: 0;
    }

    .accordion-item.active .accordion-content {
      max-height: 500px;
      padding: 1.2rem 1.8rem;
      border-top: 1px solid rgba(0, 0, 0, 0.05);
    }

    /* References */
    .reference-list {
      list-style: none;
      padding: 0;
    }

    .reference-list li {
      margin-bottom: 1.2rem;
      padding-left: 1.8rem;
      position: relative;
    }

    .reference-list li::before {
      content: '';
      position: absolute;
      left: 0;
      top: 10px;
      width: 8px;
      height: 8px;
      border-radius: 50%;
      background-color: var(--primary);
    }

    .reference-list a {
      color: var(--primary);
      text-decoration: none;
      transition: var(--transition);
      font-weight: 500;
    }

    .reference-list a:hover {
      color: var(--primary-dark);
      text-decoration: underline;
    }

    /* Footer */
    footer {
      background: linear-gradient(135deg, var(--dark), #1d2b4c);
      color: var(--white);
      padding: 3rem 0;
      text-align: center;
      position: relative;
      overflow: hidden;
    }

    footer::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      width: 100%;
      height: 4px;
      background: linear-gradient(to right, var(--primary), var(--secondary));
    }

    .footer-content {
      max-width: 800px;
      margin: 0 auto;
      position: relative;
      z-index: 1;
    }

    .footer-content h3 {
      margin-bottom: 1.2rem;
      position: relative;
      padding-bottom: 0.8rem;
      display: inline-block;
      color: var(--white);
      font-size: 1.5rem;
    }

    .footer-content h3::after {
      content: '';
      position: absolute;
      bottom: 0;
      left: 0;
      right: 0;
      width: 60px;
      height: 3px;
      background: linear-gradient(to right, var(--primary), var(--secondary));
      margin: 0 auto;
      border-radius: 3px;
    }

    .footer-content p {
      color: rgba(255, 255, 255, 0.8);
      font-size: 1.05rem;
      max-width: 600px;
      margin: 0 auto 1rem;
    }

    .footer-bottom {
      margin-top: 2rem;
      padding-top: 1.5rem;
      border-top: 1px solid rgba(255, 255, 255, 0.1);
    }

    .footer-bottom p {
      font-size: 0.95rem;
      color: rgba(255, 255, 255, 0.6);
      margin-bottom: 0;
    }

    /* Back to Top Button */
    .back-to-top {
      position: fixed;
      bottom: 30px;
      right: 30px;
      background: linear-gradient(135deg, var(--primary), var(--primary-dark));
      color: var(--white);
      width: 50px;
      height: 50px;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      text-decoration: none;
      opacity: 0;
      visibility: hidden;
      transition: var(--transition);
      z-index: 999;
      box-shadow: var(--shadow-md);
    }

    .back-to-top.visible {
      opacity: 1;
      visibility: visible;
    }

    .back-to-top:hover {
      background: linear-gradient(135deg, var(--primary-dark), var(--primary));
      transform: translateY(-5px);
      box-shadow: var(--shadow-lg);
    }

    /* Responsive Design */
    @media (max-width: 992px) {
      .timeline::after {
        left: 31px;
      }

      .timeline-item {
        width: 100%;
        padding-left: 70px;
        padding-right: 25px;
      }

      .timeline-item:nth-child(even) {
        left: 0;
      }

      .timeline-item::after {
        left: 20px;
      }

      .timeline-item:nth-child(odd)::after {
        right: auto;
        left: 20px;
      }
    }

    @media (max-width: 768px) {
      .header-top h1 {
        font-size: 2rem;
      }

      .section-title h2 {
        font-size: 1.8rem;
      }

      .stats-container {
        grid-template-columns: 1fr 1fr;
      }

      .card-header, .card-body, .content-section {
        padding: 1.5rem;
      }
    }

    @media (max-width: 576px) {
      .stats-container {
        grid-template-columns: 1fr;
      }

      nav ul {
        flex-direction: column;
      }

      nav ul li {
        width: 100%;
        text-align: center;
      }

      nav ul li a {
        padding: 0.8rem 1rem;
      }

      nav ul li a::after {
        bottom: 0.3rem;
      }

      .section-title h2 {
        font-size: 1.6rem;
      }
    }
  </style>
</head>

<body>
  <header>
    <div class="header-top" id="headerTop">
      <div class="container">
        <h1 style="color: #FFFFFF;">Uterine Leiomyosarcoma (ULMS)</h1>
        <p style="color: #f7f7f7;">A Rare and Aggressive Uterine Cancer</p>
      </div>
    </div>
    <nav id="mainNav">
      <div class="container">
        <ul>
          <li><a href="#overview">Overview</a></li>
          <li><a href="#affected-systems">Affected Systems</a></li>
          <li><a href="#symptoms">Symptoms</a></li>
          <li><a href="#diagnosis">Diagnosis</a></li>
          <li><a href="#causes">Causes</a></li>
          <li><a href="#treatment">Treatment</a></li>
          <li><a href="#statistics">Statistics</a></li>
          <li><a href="#research">Research</a></li>
          <li><a href="#resources">Resources</a></li>
        </ul>
      </div>
    </nav>
  </header>

  <main>
    <div class="container">
      <section id="overview">
        <div class="section-title">
          <h2>Overview</h2>
          <p>Understanding the Basics of ULMS</p>
        </div>

        <div class="content-section">
          <h3>What is Uterine Leiomyosarcoma?</h3>
          <p>Uterine Leiomyosarcoma (ULMS) is a rare, aggressive malignant tumor that originates from the smooth muscle layer of the uterus. It constitutes approximately 40% of all uterine sarcomas and is classified as a soft tissue sarcoma (STS). ULMS has a strong propensity to recur and metastasize, particularly to the lungs, making early detection and intervention critical for patient outcomes.</p>
          <p>Unlike benign uterine fibroids, ULMS grows rapidly, demonstrates aggressive behavior, and responds poorly to conventional treatment approaches. Understanding the characteristics, symptoms, and treatment options for this disease is essential for improving patient survival rates and quality of life.</p>
        </div>
      </section>

      <section id="affected-systems">
        <div class="section-title">
          <h2>Affected Body Systems</h2>
          <p>How ULMS Impacts Different Systems in the Body</p>
        </div>

        <div class="card">
          <div class="card-header">
            <h3>Primary and Secondary Effects</h3>
          </div>
          <div class="card-body">
            <p><strong>Reproductive System:</strong> Tumor growth disrupts uterine structure, leading to infertility and structural damage. ULMS typically originates in the myometrium (muscular layer of the uterus) and, as the disease progresses, may invade the endometrium and serosal layers. This invasive growth results in uterine dysfunction, affecting menstrual cycles and reproductive capabilities.</p>
            <p><strong>Lymphatic System:</strong> Approximately 5-11% of cases show lymph node metastasis. Although ULMS primarily metastasizes through hematogenous routes, lymphatic involvement is an important consideration, particularly in advanced stages of the disease. Lymph node metastasis typically indicates a poorer prognosis and higher risk of recurrence.</p>
            <p><strong>Respiratory System:</strong> The lungs are the most common site of metastasis, resulting in pulmonary nodules and pleural effusion. ULMS cells travel through the bloodstream to the lungs, forming secondary tumors. These metastases can lead to symptoms such as dyspnea, persistent cough, and chest pain, significantly impacting the patient's quality of life.</p>
          </div>
        </div>
      </section>

      <section id="symptoms">
        <div class="section-title">
          <h2>Symptoms</h2>
          <p>Recognizing the Signs of ULMS</p>
        </div>

        <div class="accordion">
          <div class="accordion-item">
            <div class="accordion-header">
              <h3>Abnormal Uterine Bleeding</h3>
              <div class="accordion-icon"></div>
            </div>
            <div class="accordion-content">
              <p>Abnormal uterine bleeding is one of the most common symptoms of ULMS, particularly in postmenopausal women. This may present as heavy menstrual periods, irregular menstrual cycles, or postmenopausal bleeding. Any postmenopausal bleeding should be considered a red flag and warrants immediate medical attention.</p>
            </div>
          </div>

          <div class="accordion-item">
            <div class="accordion-header">
              <h3>Pelvic or Abdominal Pain</h3>
              <div class="accordion-icon"></div>
            </div>
            <div class="accordion-content">
              <p>As the tumor grows, patients may experience pelvic or lower abdominal pain or discomfort. This pain may be constant or intermittent and sometimes worsens with physical activity or sexual intercourse. The pain is often described as dull, aching, or pressure-like in nature.</p>
            </div>
          </div>

          <div class="accordion-item">
            <div class="accordion-header">
              <h3>Vaginal Discharge</h3>
              <div class="accordion-icon"></div>
            </div>
            <div class="accordion-content">
              <p>Abnormal vaginal discharge, especially if malodorous or blood-tinged, may be a symptom of ULMS. This discharge is typically associated with tumor invasion of the endometrium. Changes in the character, amount, or odor of vaginal discharge should prompt medical evaluation.</p>
            </div>
          </div>

          <div class="accordion-item">
            <div class="accordion-header">
              <h3>Fatigue, Weight Loss, and Fever</h3>
              <div class="accordion-icon"></div>
            </div>
            <div class="accordion-content">
              <p>These are systemic symptoms of cancer that may appear in later stages of the disease. Persistent fatigue, unexplained weight loss, and intermittent fever may indicate that the disease has progressed to a more advanced stage. These symptoms result from the body's response to the malignancy and the metabolic demands of the growing tumor.</p>
            </div>
          </div>

          <div class="accordion-item">
            <div class="accordion-header">
              <h3>Dry Cough and Chest Pain (if lungs are affected)</h3>
              <div class="accordion-icon"></div>
            </div>
            <div class="accordion-content">
              <p>When ULMS metastasizes to the lungs, patients may develop a persistent dry cough, chest pain, shortness of breath, or hemoptysis (coughing up blood). These symptoms typically indicate that the disease has spread beyond the primary site and may be associated with a poorer prognosis. Pulmonary symptoms in a patient with a history of ULMS should prompt immediate evaluation for metastatic disease.</p>
            </div>
          </div>
        </div>
      </section>

      <section id="diagnosis">
        <div class="section-title">
          <h2>Diagnosis</h2>
          <p>Diagnostic Approaches and Procedures for ULMS</p>
        </div>

        <div class="content-section">
          <h3>Diagnostic Process</h3>
          <p>Diagnosis includes physical examination, ultrasound imaging, MRI, and final confirmation by histological examination. High mitotic index and necrosis indicate malignancy.</p>
          <p>Since the symptoms of ULMS can mimic those of benign uterine fibroids, accurate diagnosis can be challenging. Physicians typically employ multiple diagnostic modalities to confirm the diagnosis:</p>
          <ul>
            <li><strong>Physical Examination:</strong> The physician will check for abnormal masses or tenderness in the pelvic region.</li>
            <li><strong>Imaging Studies:</strong> Ultrasound, CT scans, and MRI can help determine the size, location, and potential spread of the tumor.</li>
            <li><strong>Biopsy:</strong> Definitive diagnosis typically requires a biopsy, which involves analyzing tumor tissue for cellular characteristics.</li>
            <li><strong>Pathological Examination:</strong> Pathologists examine tissue samples for high mitotic rates, cellular atypia, and tumor necrosis, which are hallmarks of malignancy.</li>
          </ul>
        </div>
      </section>

      <section id="causes">
        <div class="section-title">
          <h2>Causes and Risk Factors</h2>
          <p>Understanding the Etiology of ULMS</p>
        </div>

        <div class="card">
          <div class="card-header">
            <h3>Known Risk Factors</h3>
          </div>
          <div class="card-body">
            <ul>
              <li><strong>Genetic Mutations:</strong> Mutations in certain genes may increase the risk of developing ULMS. Research suggests that alterations in genes such as TP53, RB1, and PTEN are associated with the development of ULMS.</li>
              <li><strong>Hormonal Influence:</strong> Hormones such as estrogen and progesterone may play a role in the development of ULMS, although the exact mechanisms remain unclear.</li>
              <li><strong>Transformation from Benign Fibroids:</strong> While rare, there is evidence suggesting that in some cases, benign uterine fibroids may transform into ULMS.</li>
              <li><strong>Exposure to Certain Chemicals:</strong> Long-term exposure to certain environmental toxins or chemicals may increase the risk of developing ULMS.</li>
            </ul>
            <p>ULMS is not caused by viruses, is not genetically inherited in most cases, and cannot be prevented through current vaccines or health practices. The sporadic nature of ULMS makes prevention strategies challenging, emphasizing the importance of early detection and treatment.</p>
          </div>
        </div>
      </section>

      <section id="treatment">
        <div class="section-title">
          <h2>Treatment Options</h2>
          <p>Current Therapeutic Approaches for ULMS</p>
        </div>

        <div class="timeline">
          <div class="timeline-item">
            <div class="timeline-content">
              <h3>Surgical Intervention</h3>
              <p>Total hysterectomy (removal of the uterus) is the primary treatment for ULMS. For early-stage disease, this may be the only treatment required. The extent of surgery depends on the stage of the disease and individual patient factors.</p>
            </div>
          </div>
          <div class="timeline-item">
            <div class="timeline-content">
              <h3>Bilateral Salpingo-oophorectomy</h3>
              <p>Removal of the ovaries and fallopian tubes is often performed in conjunction with total hysterectomy, particularly in postmenopausal women or those with a family history. This helps reduce hormonal stimulation and potential risk of recurrence.</p>
            </div>
          </div>
          <div class="timeline-item">
            <div class="timeline-content">
              <h3>Radiation Therapy</h3>
              <p>Radiation therapy (to reduce local recurrence) may be used after surgery to reduce the risk of local recurrence. It uses high-energy rays to kill cancer cells that might remain, particularly when tumor cells are found at the surgical margins.</p>
            </div>
          </div>
          <div class="timeline-item">
            <div class="timeline-content">
              <h3>Chemotherapy</h3>
              <p>Chemotherapy (limited success in survival rate improvement) may be used for advanced or metastatic disease. Common chemotherapeutic agents include doxorubicin, ifosfamide, and gemcitabine. While chemotherapy may help control the disease, its impact on overall survival is limited.</p>
            </div>
          </div>
          <div class="timeline-item">
            <div class="timeline-content">
              <h3>Targeted Therapy and Immunotherapy</h3>
              <p>Newer treatment approaches, such as targeted therapy and immunotherapy, are being evaluated in clinical trials. These treatments aim to specifically target cancer cells or enhance the immune system's ability to fight cancer.</p>
            </div>
          </div>
        </div>
      </section>

      <section id="statistics">
        <div class="section-title">
          <h2>Statistics</h2>
          <p>Key Data and Trends in ULMS</p>
        </div>

        <div class="stats-container">
          <div class="stat-item">
            <div class="stat-number">5-6</div>
            <div class="stat-label">Cases per million annually</div>
          </div>
          <div class="stat-item">
            <div class="stat-number">50-70%</div>
            <div class="stat-label">Recurrence rate</div>
          </div>
          <div class="stat-item">
            <div class="stat-number">&lt;15%</div>
            <div class="stat-label">5-year survival rate in Stage IV</div>
          </div>
          <div class="stat-item">
            <div class="stat-number">40-60</div>
            <div class="stat-label">Most common age range (years)</div>
          </div>
        </div>

        <div class="card">
          <div class="card-header">
            <h3>Survival Rates by Stage</h3>
          </div>
          <div class="card-body">
            <p>The prognosis for ULMS is closely tied to the stage of the disease. Early diagnosis and treatment are crucial for improving survival rates:</p>
            <ul>
              <li><strong>Stage I (confined to the uterus):</strong> 5-year survival rate approximately 60-70%</li>
              <li><strong>Stage II (extension to the pelvis):</strong> 5-year survival rate approximately 40-50%</li>
              <li><strong>Stage III (extension to the abdomen):</strong> 5-year survival rate approximately 20-30%</li>
              <li><strong>Stage IV (distant metastasis):</strong> 5-year survival rate less than 15%</li>
            </ul>
            <p>These statistics highlight the importance of early detection and intervention in improving patient outcomes. The high recurrence rate, even in early-stage disease, underscores the need for close follow-up and surveillance after initial treatment.</p>
          </div>
        </div>
      </section>

      <section id="research">
        <div class="section-title">
          <h2>Current Research</h2>
          <p>Advances in ULMS Research</p>
        </div>

        <div class="card">
          <div class="card-header">
            <h3>Genomic Studies</h3>
          </div>
          <div class="card-body">
            <p>Recent research is exploring the genomic characteristics of ULMS to identify potential therapeutic targets. Researchers have identified several gene mutations associated with ULMS, which may help develop more effective targeted therapies.</p>
            <p>Genomic analysis also helps differentiate ULMS from other types of uterine sarcomas, improving diagnostic accuracy. The identification of specific molecular signatures may lead to personalized treatment approaches based on the individual tumor's genetic profile.</p>
          </div>
        </div>

        <div class="card">
          <div class="card-header">
            <h3>Immunotherapy</h3>
          </div>
          <div class="card-body">
            <p>Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, are being evaluated in clinical trials to determine their efficacy in treating ULMS. Preliminary results suggest that some patients may benefit from these treatments.</p>
            <p>Researchers are also exploring combination immunotherapy strategies to enhance the immune system's response to ULMS. These approaches aim to overcome the mechanisms by which cancer cells evade immune detection and destruction.</p>
          </div>
        </div>

        <div class="card">
          <div class="card-header">
            <h3>Targeted Therapies</h3>
          </div>
          <div class="card-body">
            <p>Drugs targeting specific molecular pathways, such as tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors, are under investigation. These drugs aim to interfere with specific molecular pathways required for cancer cell growth and spread.</p>
            <p>Personalized treatment approaches, based on the specific molecular characteristics of a patient's tumor, represent an important direction in current research. This precision medicine approach holds promise for improving outcomes in this challenging disease.</p>
          </div>
        </div>
      </section>

      <section id="resources">
        <div class="section-title">
          <h2>Patient Resources</h2>
          <p>Support and Information Resources</p>
        </div>

        <div class="content-section">
          <h3>Support Organizations</h3>
          <p>The following organizations provide information, support, and resources about ULMS:</p>
          <ul>
            <li><strong>American Cancer Society:</strong> Offers comprehensive information and support resources for ULMS.</li>
            <li><strong>National Cancer Institute:</strong> Provides up-to-date research information and clinical trial opportunities.</li>
            <li><strong>Sarcoma Foundation of America:</strong> An organization focused on sarcoma research and patient support.</li>
            <li><strong>Rare Cancer Alliance:</strong> Provides support and advocacy for patients with rare cancers.</li>
          </ul>
          <h3>Clinical Trials</h3>
          <p>Participation in clinical trials may provide patients with access to novel treatment approaches. The following resources can help patients find appropriate clinical trials:</p>
          <ul>
            <li><strong>ClinicalTrials.gov:</strong> A database of clinical trials maintained by the National Institutes of Health.</li>
            <li><strong>National Cancer Institute Clinical Trials Finder:</strong> Helps patients find clinical trials for specific cancer types.</li>
          </ul>
        </div>
      </section>

      <section id="references">
        <div class="section-title">
          <h2>References</h2>
          <p>Sources of Information</p>
        </div>

        <ul class="reference-list">
          <li><a href="https://www.cancer.org/cancer/types/uterine-sarcoma/about/what-is-uterine-sarcoma.html" target="_blank">American Cancer Society (2024). What Is Uterine Sarcoma?</a></li>
          <li><a href="https://www.mayoclinic.org/diseases-conditions/leiomyosarcoma/symptoms-causes/syc-20577215" target="_blank">Mayo Clinic (2024). Leiomyosarcoma: Symptoms and causes</a></li>
          <li><a href="https://www.cancer.gov/types/uterine/hp/uterine-sarcoma-treatment-pdq" target="_blank">National Cancer Institute (2024). Uterine Sarcoma Treatment (PDQ®)–Health Professional Version</a></li>
          <li><a href="https://www.webmd.com/uterine-cancer/understanding-endometrial-cancer-symptoms" target="_blank">WebMD (2024). Understanding Endometrial Cancer Symptoms</a></li>
          <li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039863/" target="_blank">Rizzo, A., et al. (2019). Uterine leiomyosarcoma: Current knowledge and future directions. Oncology Reports, 41(6), 3630-3638.</a></li>
          <li><a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30096-7/fulltext" target="_blank">Hensley, M. L., et al. (2018). Advances in the treatment of uterine leiomyosarcoma. The Lancet Oncology, 19(12), e721-e731.</a></li>
        </ul>
      </section>
    </div>
  </main>

  <footer>
    <div class="container">
      <div class="footer-content">
        <h3>Uterine Leiomyosarcoma (ULMS) Research</h3>
        <p>The information presented is based on current medical literature and research.</p>
        <div class="footer-bottom">
          <p>&copy; 2025 Jinyu Liang | ULMS Research Project</p>
        </div>
      </div>
    </div>
  </footer>

  <a href="#" class="back-to-top" id="backToTop">↑</a>

  <script>
    // Header title 隐藏逻辑
    const headerTop = document.getElementById('headerTop');
    const mainNav = document.getElementById('mainNav');
    const navInitialOffset = mainNav.offsetTop;
    window.addEventListener('scroll', () => {
      // 隐藏header-top
      if (window.scrollY > 0) {
        headerTop.classList.add('hide');
      } else {
        headerTop.classList.remove('hide');
      }
      // 固定nav
      if (window.scrollY >= navInitialOffset) {
        mainNav.classList.add('fixed');
      } else {
        mainNav.classList.remove('fixed');
      }
    });

    // 平滑滚动导航
    document.querySelectorAll('nav a').forEach(link => {
      link.addEventListener('click', (e) => {
        e.preventDefault();
        const targetId = link.getAttribute('href');
        const targetElement = document.querySelector(targetId);
        if (targetElement) {
          const navHeight = mainNav.offsetHeight;
          window.scrollTo({
            top: targetElement.offsetTop - navHeight,
            behavior: 'smooth'
          });
        }
      });
    });

    // Accordion
    document.querySelectorAll('.accordion-header').forEach(header => {
      header.addEventListener('click', () => {
        const item = header.parentElement;
        document.querySelectorAll('.accordion-item').forEach(accItem => {
          if (accItem !== item && accItem.classList.contains('active')) {
            accItem.classList.remove('active');
          }
        });
        item.classList.toggle('active');
      });
    });

    // Back to top
    const backToTopButton = document.getElementById('backToTop');
    window.addEventListener('scroll', () => {
      if (window.pageYOffset > 300) {
        backToTopButton.classList.add('visible');
      } else {
        backToTopButton.classList.remove('visible');
      }
    });
    backToTopButton.addEventListener('click', (e) => {
      e.preventDefault();
      window.scrollTo({ top: 0, behavior: 'smooth' });
    });
  </script>
</body>

</html>